Armenta Bioscience ApS
CVR 42358444 · Private limited company (ApS) · Active · Medium risk
Armenta Bioscience ApS is a Private limited company (ApS), founded on , based in København Ø. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 5 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 1.3m and a net result of DKK -1.4m. CEO: Matias Heide Ankjær, David Valbjørn Christensen.
Bankruptcy risk for Armenta Bioscience ApS
1.0 × the average (1.41%) · higher risk than 77% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42358444
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- Fruebjergvej 3
2100 København Ø - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 52k
- Auditor
- BDO Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 5 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 91.8% |
| Current ratio | 1,083% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 3 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 611 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -677k | DKK -434k |
| Net profit | DKK -1.4m | DKK -1.4m |
| Equity | DKK 1.3m | DKK 684k |
| Total assets | DKK 1.4m | DKK 733k |
| Cash | DKK 676k | – |
| Short-term debt | DKK 114k | – |
| Avg. employees | 4 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · BDO Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 140 | ||
| 1 Jan 2024 – 31 Dec 2024 | 168 | ||
| 1 Jan 2023 – 31 Dec 2023 | 127 | ||
| 1 Jan 2022 – 31 Dec 2022 | 142 | ||
| 28 Apr 2021 – 31 Dec 2021 | 152 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Matias Heide Ankjær | Current | |
| CEO | David Valbjørn Christensen | Current | |
| CEO | Josef Christensen | ||
| Board | Mikkel Skorkjær Kongsfelt | Current | |
| Board | Katharine Sarah Holland | Current | |
| Board | Kristoffer Tømmeraas | Current | |
| Board | David Valbjørn Christensen | ||
| Owner (5%) | Kempf ApS | Current | |
| Owner (5%) | Niklis Holdings ApS | Current | |
| Owner (25%) | Wallbear Invest ApS | Current | |
| Owner (25%) | Stem Cell ApS | Current | |
| Owner (5%) | Accelerace Invest II K/S | Current | |
| Owner (100%) | MATIAS ANKJÆR INVEST Aps | ||
| Owner (33%) | David Valbjørn Christensen | ||
| Owner (33%) | MATIAS ANKJÆR INVEST Aps | ||
| Owner (10%) | JChristensen Invest ApS | ||
| Owner (10%) | Kempf ApS | ||
| Owner (10%) | Niklis Holdings ApS | ||
| Owner (33%) | David Valbjørn Christensen | ||
| Owner (33%) | MATIAS ANKJÆR INVEST Aps | ||
| Owner (10%) | Kempf ApS | ||
| Owner (10%) | Niklis Holdings ApS | ||
| Owner (33%) | Wallbear Invest ApS | ||
| Owner (33%) | Stem Cell ApS | ||
| Founder | MATIAS ANKJÆR INVEST Aps | Current |
The CEOs' other companies
Matias Heide Ankjær – 3 other companies
- INVESTX A/S Active
- MATIAS ANKJÆR INVEST Aps Active
- Stem Cell ApS Active
David Valbjørn Christensen – 1 other companies
- Wallbear Invest ApS Active
Josef Christensen – 1 other companies
- JChristensen Invest ApS Active
Address history (3 moves)
| Fruebjergvej 3, 2100 København Ø | |
| c/o Matias Ankjær, Centrifugevej 374, 2800 Kongens Lyngby | |
| c/o Matias Ankjær, Faste Batteri Vej 52, 2. th, 2300 København S | |
| c/o Matias Ankjær, Nørre Allé 6, 1. 10, 2200 København N |
Former names
| Armenta Bioscience ApS | – now |
| Gephion Bio ApS | – |
| Meat Tomorrow ApS | – |
Other companies at the same address
- A DIMENSION GROUP A/S Bankrupt
- A-SYNTESE BIOTECH ApS Bankrupt
- ABSTRACTION ApS Bankrupt
- ADURA ApS Bankrupt
- AFVIKLINGSSELSKABET AF 8.2.1999 A/S Bankrupt
- ALLEGENETICS DIAGNOSTICS LABORATORY ApS Bankrupt
- ANSARI GROUP S.M.B.A. Bankrupt
- AQUALIFE A/S Bankrupt
- AREA NETWORKS ApS Bankrupt
- ASD Group Denmark ApS Bankrupt
- Afsluttet Projektselskab BLN ApS Bankrupt
- Andersen & Andersen IVS Bankrupt
- Andersentraveller ApS Bankrupt
- ApS VICTORIA STREET KOMPLEMENTAR Bankrupt
- Autocycle International ApS Bankrupt
- BB Ejendomme 2015 IVS Bankrupt
- BB Jyllands investering IVS Bankrupt
- BB Jyllands projekt IVS Bankrupt
- BINCORE GROUP A/S Bankrupt
- BINCORE INDUSTRIES A/S Bankrupt
- BLUSENSE DIAGNOSTICS APS Bankrupt
- BRUUNS INVEST ApS Bankrupt
- BRUUNS REVISION ApS Bankrupt
- BUILD ApS Bankrupt
- Baunsgaard Technologies ApS Bankrupt
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Armenta Bioscience ApS
Has Armenta Bioscience ApS gone bankrupt?
No, Armenta Bioscience ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Armenta Bioscience ApS?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the CEO of Armenta Bioscience ApS?
Matias Heide Ankjær, David Valbjørn Christensen are the CEOs of Armenta Bioscience ApS.
Who is the auditor of Armenta Bioscience ApS?
Armenta Bioscience ApS most recently used BDO Statsautoriseret Revisionspartnerselskab.
When was Armenta Bioscience ApS founded?
Armenta Bioscience ApS was founded on 28 April 2021.
What is the equity of Armenta Bioscience ApS?
Equity was DKK 1.3m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.